Rize Oncology Inc. (RZONF)

Overview

Rize Oncology Inc. is a biopharmaceutical company that focuses on the development of cutting-edge precision gene editing technologies aimed at enhancing human therapeutics, specifically in the realm of oncology. Targeting soft tissue sarcoma, a rare and aggressive form of cancer, the company is committed to addressing the unmet medical needs of patients with challenging tumor types. Founded in 2018 and headquartered in Kelowna, British Columbia, Canada, Rize Oncology Inc. operates within the biotechnology sector, striving to advance innovative treatments through its proprietary GeneTether platform. In January 2025, the company rebranded from its former name, GeneTether Therapeutics Inc., reflecting its dedication to precision medicine. The visionary leadership team includes CEO Roland Boivin, Chairman Daren Graham, and co-founders Dr. William James Garner and Dr. R. Geoffrey Sargent. With a small but skilled workforce, Rize Oncology continues to make significant contributions to the landscape of cancer therapies.

Products and Services

• STS-201

  STS-201 is Rize Oncology's lead candidate, developed as a small-molecule drug specifically targeting soft tissue sarcoma. This innovative therapeutic aims to inhibit tumor growth and enhance patient outcomes, with the potential for application in various other cancers and proliferative diseases. STS-201 represents a significant advancement in cancer treatment approaches and is at the forefront of the company's research efforts.

• GeneTether Platform

  The GeneTether platform is a pioneering gene editing technology utilized by Rize Oncology to create high-efficiency therapies. This platform supports the development of precision medications aimed at delivering targeted treatments that address the unique genetic makeup of individual tumors. Through the GeneTether platform, Rize Oncology aims to revolutionize the treatment landscape for oncology and expand its applications beyond traditional methods.